Everist Gets External Validation of Colorectal Cancer Risk Test
Ann Arbor-based Everist Genomics, a company developing gene-based molecular assays for the prediction of cancer recurrence, last week announced the positive results of the first external validation study of its OncoDefender-CRC colorectal cancer recurrence test.


